Minoxidil Plus product seizure Aug. 3 is latest action in long-running case of Upjohn v. Medtron.
Executive Summary
MINOXIDIL PLUS PRODUCT SEIZURE AUG. 3 IN NEW YORK CITY is the latest action in a long-running legal effort by Upjohn to bar a Manhattan salon from capitalizing on Rogaine labeling for treatment of hair loss. The seizure of "Minoxidil Plus" came after Manhattan federal court Judge Shirley Wohl Kram ruled July 19 that the Hair & Skin Treatment Center (formerly New York Hair Labs, formerly Medtron) was in contempt of the court's 1990 and 1992 injunctions enjoining the defendant from the "manufacturing, sale, distribution, advertisement, and promotion" of products covered by Upjohn's Rogaine patents.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth